Oncolysin M

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOncolysin M
Drug Alias NameAnti-CD33-bRAnti-My9-blocked ricinAnti-My9-bROncolysin-M
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsProtein biosynthesis inhibitors
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunogen IncDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDana-Farber Cancer InstituteImmunogen Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A